GlassScriptPhysician profile
Jack R Eades
NPI 1992890727
$237,286.81
in general payments reported to CMS, 2019-2025
37 companies · $92K in 2025
The $92K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,290 · 2020: $4,559 · 2021: $2,299 · 2022: $19K · 2023: $40K · 2024: $70K · 2025: $92K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $150K · Travel and Lodging: $26K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $6,573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $149,669.92 |
| Travel and Lodging | $26,300.84 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,372.50 |
| Food and Beverage | $6,573.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $202,090.11 | 2019-2025 | Ruconest, Joenja |
| Astrazeneca Pharmaceuticals LP | $18,045.12 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Pfizer INC. | $6,657.45 | 2019-2024 | |
| Csl Behring | $2,864.14 | 2019-2025 | Haegarda, Hizentra |
| Glaxosmithkline, LLC. | $2,702.53 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $684.75 | 2019-2023 | Dupixent |
| Octapharma USA, INC. | $656.20 | 2019-2025 | Panzyga |
| Biocryst US Sales Co., LLC | $576.60 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $388.13 | 2019-2022 | |
| Kaleo, INC. | $281.08 | 2019-2023 | Auvi-Q |
| Teva Pharmaceuticals USA, INC. | $274.75 | 2019-2022 | |
| Optinose US, INC. | $213.61 | 2019-2024 | |
| Abbvie INC. | $200.78 | 2022-2024 | |
| Genzyme Corporation | $196.75 | 2019-2024 | |
| Amgen INC. | $185.06 | 2021-2025 | Tezspire |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $180.58 | 2022-2025 | Cuvitru, Hyqvia, Takhzyro |
| Novartis Pharmaceuticals Corporation | $157.70 | 2019-2023 | |
| Grifols USA, LLC | $128.38 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $111.94 | 2019 | |
| Hikma Pharmaceuticals USA | $94.59 | 2019-2022 | |
| Eyevance Pharmaceuticals LLC | $59.08 | 2021 | |
| Hospira, INC. | $57.69 | 2022 | |
| Incyte Corporation | $57.26 | 2022 | |
| Phadia US INC. | $57.02 | 2020-2021 | |
| Horizon Therapeutics Plc | $51.88 | 2019-2022 | |
| Covis Pharma Gmbh | $49.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.26 | 2020 | |
| Circassia INC. | $36.02 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $29.36 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $27.47 | 2022 | |
| Adma Biomanufacturing LLC | $24.65 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $24.40 | 2022 | |
| Shire North American Group INC | $23.87 | 2019 | |
| Blueprint Medicines Corporation | $21.26 | 2023 | |
| Ani Pharmaceuticals, INC. | $20.41 | 2025 | Purified Cortrophin Gel |
| Jubilant Hollisterstier LLC | $17.56 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Eades listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.